Navigation Links
AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
Date:5/30/2012

30 days after the closing.  The securities offered have not been registered under the Securities Act and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act.

About AcelRx Pharmaceuticals
Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain, and AcelRx plans to initiate a Phase 2 study funded by a grant from USAMRMC, contingent on approval of the proposed clinical protocol for the study by USAMRMC.

This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities. For additional information, please refer to AcelRx's current report on Form 8-K to be filed with the Securities and Exchange Commission with respect to the private placement.'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 27, 2015 Research and Markets ( ... "3D Metrology Market by Product (CMM, ODS, and VMM), ... & Geography (North America, Europe, APAC, RoW) - Global ... The 3D metrology market was valued ... grow at a rate of 7.11% during the forecast ...
(Date:7/29/2015)... Inc., a privately-held regenerative medicine company with the first stem cell-derived ... today announced the opening of a second site in its Phase ... olerability, and E fficacy of VC-01™ Combination P roduct ... the first in Canada , will be at ... Alberta.  The lead Edmonton ...
(Date:7/29/2015)... 29, 2015 According to a ... Active Pharmaceutical Ingredients (API) Market - Global Industry Analysis, ... " the global active pharmaceutical ingredients market was valued ... to reach USD 185.9 billion by 2020, expanding at ... 2014 to 2020. Full Research Report on ...
Breaking Medicine Technology:Global 3D Metrology Market 2015-2020: Products (CMM, ODS, and VMM) & Applications (Automotive, Aerospace, Energy & Power, Medical and Electronics) 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 2Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 3Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 4Active Pharmaceutical Ingredients Market Expected to Reach USD 185.9 Billion Globally in 2020: Transparency Market Research 5
... PAUL, Minn., March 7, 2012  Prime Therapeutics (Prime), a ... a leader in the U.S. biopharmaceutical market and subsidiary ... agreement bringing the first outcomes-based rebate contract for a ... As an integrated PBM with its health plan clients, ...
... WESTLAKE VILLAGE, Calif., March 7, 2012 Denise Noyer-Erez, ... Month" in honor of all those affected by the ... million women and girls in the United States.  In ... and immunological disease in which the endometrium—uterine lining—moves outside ...
Cached Medicine Technology:Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif® 2March is Endometriosis Awareness Month 2
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Angelo’s FabriClean, ... its new service: water damage restoration of carpets and rugs. The company will now ... as for commercial clients. , An overflowing overhead tank, rain leaking through an ...
(Date:7/29/2015)... ... July 29, 2015 , ... The healthcare analytics market is ... region. Factors such as the rising pressure to curb healthcare costs, big data ... venture capital investments are driving market growth. Check 149 data tables & 57 ...
(Date:7/29/2015)... ... July 29, 2015 , ... On July 26th ... by the FDA for nicotine laced liquid products. Their report says cigarette use ... considerably. E-Cigarettes are particularly troublesome to addiction professionals as many of the candy ...
(Date:7/29/2015)... Willingboro, NJ (PRWEB) , ... July 29, 2015 , ... ... Jersey to now offer the Rotation Medical Rotator Cuff System, a new implant to ... “bioinductive” implant is designed to foster natural regeneration of additional tendon tissue, which could ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... CanAm Enterprises, ... by USCIS over the past month! I-829 approvals have been granted to investors in ... Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Water Damage Restoration For Residential and Commercial Accounts 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3
... the Gulf Coast Region Work Together to Prepare,Vulnerable ... 11 As Hurricane Ike,approaches the Gulf Coast, ... procedures in advance of a potential healthcare,crisis, threatening ... therapy. In preparation for this pending disaster,scenario, the ...
... the Drug Enforcement Administration explores the many costs ... and consequences of illegal drugs, LOS ... America: Opening Eyes to the Damage,Drugs Cause will open in Los ... May 3, 2009 the exhibit will explore the,science behind illegal drug ...
... MINRAD,International, Inc. (Amex: BUF ) today ... wholly-owned subsidiary of RxElite Inc. (OTC,Bulletin Board: RXEI), ... RxElite Holdings, Inc.,s rights to be the exclusive ... the United,States. Minrad has decided to move into ...
... Hurricane Ike nears the Gulf Coast, evacuating Texans are ... Red Cross Safe and Well,Web site., WASHINGTON, Sept. ... Friday evening or early Saturday morning,affecting areas of Texas ... to Texas, its message to residents is urgent: listen ...
... Minn., Sept. 11 A study led by ... published this week in,the Journal of the American ... effective., Lead author David Cook, M.D., an ... at Mayo Clinic, worked with researchers,from Mayo and ...
... GAITHERSBURG, Md. and TOKYO, Sept. 11 MedImmune, ... Co., Ltd, a,subsidiary of SBI Holdings, Inc., announced ... collaboration agreement to develop and commercialize,SBI Biotech,s anti-ILT7 ... (SLE) and other autoimmune diseases. MedImmune has,global rights ...
Cached Medicine News:Health News:Texas Home Oxygen Therapy Community Braces for Hurricane Ike 2Health News:Target America Exhibit Opens at the California Science Center October 2, 2008 2Health News:Target America Exhibit Opens at the California Science Center October 2, 2008 3Health News:Target America Exhibit Opens at the California Science Center October 2, 2008 4Health News:MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc. 2Health News:MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc. 3Health News:American Red Cross Urges, 'Prepare for Ike' 2Health News:American Red Cross Urges, 'Prepare for Ike' 3Health News:Mayo Clinic, McMaster University Research Review Shows Internet-based Instruction Effective for Teaching Health Care Professionals 2Health News:MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech 2
Permanent, sutureless, epicardial pacing leads...
Bipolar Ventricular Lead...
The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: